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 INTRODUCTION  
 India has an ancient heritage of traditional medicine. Traditional medicine is a very 
important part of health care. Most of the population in the developing countries still relies 
mainly on indigenous traditional medicines for satisfying their primary health care needs. 
Materia medica of India provides much information on the folklore practices and traditional 
aspects of therapeutically important natural product. Today we find in every country the 
folklore living in the nook and corner are habituated to use their plant resources. They have 
developed ethnic systems of medicines. Some of them have developed based on prolonged 
experience (1). 
 Traditional use of herbal medicine is the basis and integral part of various cultures, 
which was developed within an ethnic group before the developed and spread of modern 
science. Herbal drugs constitute a major part in all the traditional systems of medicine. These 
have made a great contribution in maintaining human health. A majority of the world’s 
population still rely on herbal medicines to meet its health needs. The practice continues 
today because of its biomedical benefits and its place in culture beliefs in many part of world. 
 India, china and several other nations have an ancient tradition of herbal remedies. 
The written records in Ayurveda, the ancient system of medicine in India, contain more than 
800 herbal remedies. The Charaka Samhita and Sushruta Samhita are two treasure troves 
containing knowledge of plant based drugs and are even today, held in the highest esteem the 
world over. 
 Inspite of all the advances in therapeutics, Diabetes still remain a major cause of 
morbidity and mortality in the world. Diabetes Mellitus is the most common metabolic 
disorder known to the ancient Indian physician some 3000 years ago, as can be seen, from the 
medicinal texts such as Charaka Samhita and Sushruta Samhita. They have discussed the 
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honey urine in detail. The most ancient medicinal systems of India provide information that 
madhumeha (diabetes) has long been treated with various herbs and herbomineral drugs. It is 
observed that some are used as anti-diabetic medicine by folklore. Notable among them are 
the use of fresh juice of Bael, Onion and Garlic. 
 However, the name Diabetes was given by the two Roman physician Celsius and 
Aretaeus in 1st A.D in 1921.Banting and Best solved the problem of Diabetes to a great extent 
by discovering Insulin as a therapeutic agent in Insulin Dependent Diabetes Mellitus. The 
first oral hypoglycemic agents suitable for clinical use were the sulfonylureas developed by 
Auguste Loubatieres in the year 1940.(2) Conventionally, insulin dependent diabetes mellitus 
is treated with exogenous insulin(3) and non-insulin-dependent diabetes mellitus with 
synthetic oral hypoglycemic agents like sulphonylureas and biguanides(4). However the 
hormonrifails as curative agent for complications of diabetes and synthetic oral drugs produce 
adverse health effects.(5)  Therefore, different medicinal systems are using the active plant 
constituents, which discovered as natural hypoglycemic medicine came from the virtue of 
traditional knowledge.(6)  Asia’s large population and rapid economic development have 
made it an epicenter of the epidemic.  Asian populations tend to develop diabetes at younger 
ages and lower BMI levels. Several factors contribute to accelerated diabetic epidemic in 
Asians, including the “normal-weight metabolically obese” phenotype, high prevalence of 
smoking and heavy alcohol use; high intake of refined carbohydrates (e.g. White rice) and 
dramatically decreased physical activity levels. 
 Estimates for the worldwide prevalence of diabetes have increased from around 60 
million in 1980 to about 118 million in 1995 and are set to increase to 220 million by the year 
2010(Amoes et al., 1997). According to the International Diabetes Federation (IDF), Diabetes 
affects at least 285 million people worldwide, and that number will be expected to reach 438 
million by the year 2030. 
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 More than 400 different plants and plant extracts have been described as reputedly 
beneficial for the diabetic patient. Most of these plants have been claimed to possess 
hypoglycemic properties but most claims are anecdotal and few have received adequate 
medical or scientific evaluation. Those that have been evaluated may be grouped into three 
categories: 
1. Plants from which a reputedly hypoglycemic compound or partially characterized 
hypoglycemic fraction has been prepared. 
2. Plants reported to exert a hypoglycemic effect, but the nature of the active principle is 
unestablished. 
3. Plants that reputedly exert a hypoglycemic effect, but the scientific evidence is 
equivocal. These categories exclude the numerous traditional plants for which an 
independent scientific or medical has not been published. 
 Portulaca quadrifida L. is an important medicinal herb and this plant is a small, 
diffuse, annual and erect herb found throughout the tropical parts of India. It is said to be 
useful in asthma, cough, urinary discharges, inflammations and ulcers. A poultice of the plant 
is applied in abdominal complaints, erysipelas, and haemorrhoids. Portulaca quadrifida L. 
has been reported to possess antifungal activity against Aspergillus fumigates and Candida 
albicans. The effect of ethanolic extract of Portulaca quadrifida L. on central and peripheral 
nervous system were studied by using spontaneous motor activity, in vivo muscle relaxant 
activity (Grip strength) and anticonvulsant activity(11).  However, till date there has been no 
investigation supporting the anti-diabetic properties of this plant. Hence, this study has been 
taken with an aim to evaluate the anti-diabetic potential of ethanolic extract of whole plant of 
Portulaca quadrifida L. in in-vitro and in-vivo Streptozotocin model. 
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AIM AND OBJECTIVES 
 
1. Phytochemical evaluation of the whole plant of ethanolic extract of Portulaca quadrifida L.  
 
2. To determine the glucose diffusion property of the prepared extract of the Portulaca  
 
quadrifida L. using dialysis tube and GOD-POD kit. 
 
3. To evaluate the safety of the effective extract of Portulaca quadrifida L. by acute toxicity 
study in Wistar albino rats. 
 
4. To investigate the in-vivo anti diabetic effect of active extract of Portulaca quadrifida L.  
 
in Streptozotocin induced diabetic Wistar albino rats. 
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REVIEW OF LITERATURE 
DIABETES MELLITUS 
 The word “Diabetes” is derived from “Greek” word “Diabainein” which means “to 
pass through”. It is characterized by an excess of glucose in blood and urine, hunger, thirst 
and gradual loss of weight. Insulin is a hormone which regulates the carbohydrates and 
triglyceride metabolism through its action at several sites and facilitates the entry of glucose 
into the cell. Insulin also stimulates the synthesis of glucokinase and moderates the degree of 
gluconeogenesis. In the diabetic patient, there is an aberration in the functioning of insulin. 
WHO CLASSIFICATION OF DIABETES MELLITUS 
1) TYPE 1 DIABETES MELLITUS(12)  
The hallmark also known as Insulin Dependent Diabetes Mellitus (IDDM). It is not 
associated with obesity, and may be associated with acidosis or ketosis. Administration of 
insulin is essential in patients with type I diabetes. Type I diabetes is further subdivided into 
immune and idiopathic types. 
The immune form is the most common form of type I diabetes. Although most 
patients are younger than 30 years of age at the time of diagnosis, the onset can occur at any 
age. When it occurs at infancy (due to congenital disorder) or in childhood, it is called 
Juvenile diabetes. Susceptibility appears to involve a multi factorial genetic linkage, but only 
15-20% of patients have a positive family history. 
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Causes  
i. Degeneration of β cells in the islets of Langerhans of pancreas. 
ii. Destruction of β cells by viral infection. 
iii. Congenital disorder of β cells. 
iv. Destruction of β cells due to autoimmune disorder where there is development 
of antibodies against β cells. 
2) TYPE 2 DIABETES MELLITUS 
 Type 2 diabetes is characterized by tissue resistance to the action of insulin combined 
with a relative deficiency in insulin secretion. It usually occurs after 40 years; hence it is 
called as maturity onset diabetes mellitus. It is also known as adult-onset diabetes or Non-
Insulin Dependent Diabetes Mellitus (NIDDM). 
 The impaired insulin action affects fat metabolism, resulting in increased free fatty 
acid flux and triglyceride levels, and reciprocally low high-density lipoprotein (HDL) levels. 
Causes  
 In this type of diabetes, the structure and function of β cells and the blood level of 
insulin are normal. The diabetes develops due to the absence or reduced number of insulin 
receptors in the cells of the body.  
The major causes for type 2 diabetes are: 
Heredity disorders 
 Heredity disorders which may be associated with DM or impaired glucose tolerance 
can be subdivided into syndromes such as maternally inherited diabetes, down, turner and 
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klinefelter syndromes, metabolic diseases such as cystic fibrosis and hemochromatosis. 
Patients with a heredity disorder run a higher risk of developing DM. 
Endocrine disorders 
 It is very common ‘in some of the disorders like Gigantism, Acromegaly, and 
Cushing’s syndrome. The hyperglycemia in these conditions causes excess stimulation, in 
turn causes burning out and degeneration of β cells. The β cells exhaustion leads to 
permanent DM. This type of DM is called secondary diabetes. 
3) GESTATIONAL DIABETES (GDM)(13) 
 It is defined as any abnormality in glucose levels noted for the first time during 
pregnancy and resolves after delivery. Gestational diabetes mellitus develops during the 
second or third trimester of pregnancy in about 2% of pregnancies and is treated by diet. 
During pregnancy, the placenta and placental hormones create an insulin resistance that is 
most pronounced in the last trimester. However, insulin injections may be required. Women 
who have GDM are at higher risk for developing Type 2 diabetes mellitus within 5-10 years. 
4) MATURITY ONSET DIABETES IN YOUNG (MODY) 
 MODY is defined as hyperglycemia diagnosed before the age of 25 years and 
treatable for more than 5 years without insulin. Patients with MODY are found to have 
mutation in the glucokinase (Hexokinase IV) gene on chromosome 7p, and the primary cause 
of their NIDDM is due to reduction in glucose stimulated insulin secretion. This disease was 
shown to be linked genetically to ADA (adenosine deaminase) locus on chromosome 20q. 
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5) GENETICS(14) 
 Susceptibility to both IDDM and NIDDM is determined to a substantial extent by 
genetic factors. These probably interact with an environmental trigger to induce expression of 
the disease state. The major contribution comes from a gene or genes within the HLA region, 
on the short arm of chromosome 6, at least one of which lies close to or within the DQ sub 
region. 
 There is a stronger inheritance pattern for type 2 diabetes. Those with first-degree 
relatives with type 2 have a much higher risk of developing type 2 diabetes. 
SIGNS AND SYMPTOMS OF DM(15) 
 These are mainly due to hyperglycemia with decreased utilization of glucose by cells; 
as a result, there is an extracellular glucose excess and intracellular glucose deficiency, a 
situation called starvation in the midst of plenty. 
1. Hyperglycemia (raised blood glucose), it predisposes to infection like boils and 
urinary tract infection. 
2. Glycosuria (presence of glucose in the urine) 
3. Polyuria (excessive urine production) 
4. Dehydration  
5. Polydipsia (increased thirst) is a result of the dehydration that results from the osmotic 
diuresis. 
6. Polyphagia (excessive eating)- low glucose utilization by glucostat cells of 
ventromedial nucleus in hypothalamus(satiety center) results in no inhibition of lateral 
nucleus in hypothalamus(feeding center) which eventually produces increased hunger. 
7. Loss of weight. 
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8. Ketonuria. 
9. Poor resistance to infections due to protein depletion. 
10. Hyperlipedemia (abnormally high serum lipid levels). Insulin deficiency decreases 
LDL receptor availability, which decreases serum cholesterol clearance. This 
decreased clearance produces hypercholesterolemia, or high blood cholesterol. 
11. Electrolyte depletion. 
DIAGNOSIS OF DIABETES(16) 
 Diabetes can be confirmed by estimating the blood glucose level. This may be 
performed using the Glucometer and Blood glucose test strips with small drop of blood 
from finger. 
Test for blood glucose levels are: 
a) Fasting plasma glucose (FPG) test 
 It is also known as fasting blood sugar test. It measures blood glucose in a person who 
has not eaten anything for at least 8 hours. 
Plasma glucose result (mg/dL) Diagnosis  
99 or below Normal  
100 – 125 Pre-diabetes (impaired fasting glucose) 
126 or above Diabetes  
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b) Postprandial blood glucose test 
 It is a test that determines the amount of glucose in the blood 2 hours after a meal. 
Plasma glucose result (mg/dL) Diagnosis  
<140 mg/dL Normal  
140-200 mg/dL Pre-diabetes (impaired glucose tolerance) 
>200 mg/dL Diabetes  
 
c) Oral glucose tolerance test (OGTT) 
 This test is done to assess the glucose level of a person, 2 hours after the 
administration of 75 gms of glucose dissolved in water with overnight fasting for atleast 8 
hours. 
2-hour plasma glucose result (mg/dL) Diagnosis  
139 or below Normal  
140-199 Pre-diabetes (impaired glucose tolerance) 
200 or above Diabetes  
 
d) Glycosylated haemoglobin test 
 A test that measures the amount of haemoglobin bound to glucose. It indicates the 
amount of sugar in a person’s blood during the past 2-4 months. It is used to monitor 
effectiveness of diabetes treatment. 
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Plasma glucose result (mg/dL) Diagnosis  
4% - 6% Normal  
More than 6% Diabetes  
 
e) Random plasma glucose test 
 It is also known as casual plasma glucose test, which measures blood glucose level 
randomly. Symptoms of diabetes + random plasma glucose concentration ≥ 200 mg/dL 
(11.1mmol/l) is the diagnostic criteria for diabetes mellitus. 
COMPLICATIONS OF DM(17) 
(i)Diabetic ketoacidosis is a serious consequence of poorly controlled IDDM. It is 
characterized by elevated blood glucose level, ketonemia, increased serum osmolarity and 
elevated stress hormone levels (the counter regulatory hormones to insulin – cortisol, GH, 
glucagon, epinephrine). These elevated hormones aggravate the metabolic disorder. The 
patients have acidosis and decreased vascular volume. 
 (ii)Nonketotic Hyperosmolar Coma (NHC) can occur with either IDDM or NIDDM. 
People with NHC have extremely high serum hyperosmolarity and glucose. 
 (iii)Insulin shock is produced due to the administration of excessive amounts of 
insulin which can cause confusion, convulsions, loss of consciousness and even death. 
LONG TERM SEQUELAE OF DM 
 Long-term problems associated with DM include Neuropathies, Nephropathies, 
Microangiopathies, Macroangiopathies, and Retinopathies. 
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(i)Neuropathies: Peripheral nerve damage (neuropathy) can occur as a result of metabolic or 
osmotic damage to neurons or Schwann cells. Diabetic patients can exhibit sensory loss, 
paraesthesia and even pain as a result of the neurologic damage. Neuronal transmission is 
slowed. 
(ii)Nephropathies: Diabetes is a common cause of renal failure (nephropathy). The 
glomerular capillary basement membrane thickens, which is thought to produce 
glomerulosclerosis and subsequent renal insufficiency. 
(iii)Microangiopathies: microscopic changes occur in the microcirculation with prominent 
thickening of capillary basement membranes. 
(iv)Macroangiopathies: Atherosclerosis develops in diabetic patients at an accelerated rate. 
Diabetic patients are more likely to have coronary artery disease and myocardial infarction 
than are non-diabetic individuals. 
(v)Retinopathies: Retinal abnormalities develop in diabetic patients and are a major cause of 
blindness in the United States. The retinal changes are characterized by aneurysms, increased 
capillary permeability, small retinal hemorrhages and excessive micro vascular proliferation. 
(vi)Nonretinal Visual Problems: As blood glucose and blood osmolarity rise, the volume of 
the lens rise, distorting vision and the diabetic patients commonly have cataracts. 
CHEMICAL AGENTS CAPABLE OF INDUCING DIABETES(18) 
 Alloxan 
 Streptozotocin  
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ALLOXAN INDUCED DIABETES 
 Alloxan, a cyclic urea analogue, was the first agent producing permanent diabetes in 
animals. It is a highly reactive molecule readily reduced to diuleric acid, then auto-oxidized 
back to alloxan resulting in the production of free radicals. These free radicals damage the 
DNA of β-cells and cause cell death. Second mechanism proposed for alloxan is its ability to 
react with protein SH groups, especially the membrane proteins like glucokinase on the β-
cells, finally resulting in cell necrosis. 
Drawbacks  
 High mortality in rats. 
 Causes ketosis due to free fatty acid generation. 
 Diabetes induced is reversible. 
 Some species like guinea pigs are resistant to its diabetogenic action. 
STREPTOZOTOCIN INDUCED DIABETES 
STZ [2-deoxy-2-(3-methyl-3-nitrosourea) 1-D-glucopyranose] is a broad-spectrum 
antibiotic, which is produced from Streptomyces achromogens. STZ causes β-cell damage by 
process of methylation, free radical generation and Nitric oxide production. 
Advantages  
STZ has almost completely replaced alloxan for inducing diabetes because of: 
 Greater selectivity towards β-cells 
 Lower mortality rate and 
 Longer or irreversible diabetes induction. 
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Disadvantage 
 Guinea pigs and rabbits are resistant to its diabetogenic action.  
HORMONE-INDUCED DIABETES MELLITUS 
 Dexamethasone, a long acting glucocorticoid, is used to produce NIDDM at a dose of 
2-5mg/kg i.p. twice daily over a number of days in rats. 
INSULIN ANTIBODIES-INDUCED DIABETES 
 Giving bovine insulin along with CFA to guinea pigs produces anti-insulin antibodies. 
Intravenous injection of 0.25-1.0 ml guinea pig anti-insulin serum to rats induces a dose 
dependent increase in blood glucose levels up to 300%. This unique effect to guinea pig anti-
insulin serum is due to neutralization of endogenous insulin by the insulin antibodies. It 
persists as long as the antibodies are capable of reacting with insulin remaining in the 
circulation. Slow i.v. infusion or i.p. injection prolongs the effect for more than a few hours. 
However, large doses and prolonged administration are accompanied by ketonemia, 
ketonuria, glycosuria and acidosis and are fatal to animals. After lower doses, the diabetic 
syndrome is reversible after a few hours. 
VIRAL AGENTS-INDUCED DIABETES 
 Viruses are thought to be one of the etiologic agents for IDDM. Viruses may produce 
diabetes mellitus by: 
 Infecting and destroying of β-cells in pancreas,  
 A less infecting or cytologic variant producing a comparable damage by eliciting 
immune auto reactivity to the β-cells, 
 Viruses producing systemic effect, not directly affecting the β-cells. 
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Various human viruses used for inducing diabetes include RNA picornoviruses, 
Coxsackie-B4 (CB4), encephalomylocarditis (EMC-D and M variants), Mengo-2T, as well as 
two other double stranded RNA viruses, reovirus and lymphocytic choriomeningitis virus 
(LMCV, Armstrong variant). 
SURGICALLY INDUCED DIABETES 
 Surgical removal of all or part of the pancreas can induce Diabetes Mellitus. In partial 
pancreactectomy more than 90% of the organ must be removed to produce diabetes. 
Depending on the amount of intact pancreatic cells, diabetes may range in duration from a 
few days to several months. Total removal of the pancreas results in an insulin-dependent 
form of diabetes, and insulin therapy is required to maintain experimental animals. The 
portion of the pancreas usually left intact following a subtotal pancreatic resection is typically 
the anterior lobe or a portion thereof. 
Disadvantages  
 Surgical removal of pancreas results in loss of α- and δ-cells in addition to β-cells. 
This causes loss of counter-regulatory hormones, glucagon and somatostatin. 
 There is a loss of the pancreatic enzymes necessary for proper digestion; therefore, the 
diet must be supplemented with pancreatic enzymes. 
MANAGEMENT OF DIABETES MELLITUS(19) 
 The goals of treatment for diabetes are to reduce and control blood glucose levels, 
relieve the symptoms of the disease and prevent complications. Intensive treatment and 
careful control of blood glucose levels can reduce the risk of complications of diabetes.(20) 
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I. NON PHARMACOLOGICAL INTERVENTIONS: 
The major environmental factors that increase the risk of type 2 diabetes, presumably 
in the setting of genetic risk are nutrition and sedentary lifestyle with consequent over weight 
and obesity. Medical nutrition therapy (i.e., diet) and exercise are important aspects of non-
pharmacologic treatment for diabetes. Weight loss is a vital part of treatment for type 2 
diabetes because it can help improve the sensitivity of cells to insulin and the uptake of 
glucose by cells. 
A goal of medical nutrition therapy is to attain and maintain blood glucose levels in 
the normal range or as close to normal as possible. Patients with type 2 diabetes typically 
have dyslipidemia and another goal for these patients is to improve the lipid profile. 
II. PHARMACOLOGICAL INTERVENTIONS: 
A) Injectable anti-diabetic agents(21) 
1) INSULIN: 
 All patients with type 1 diabetes require insulin injections. Patients with type 2 
disease who have multiple symptoms of hyperglycemia are pregnant or have ketosis also 
should use insulin injections. Currently, insulin used for treatment is derived from beef and 
pork pancreas as well as recombinant (human) DNA technology.  
 In the 1980s, the human insulin was produced by recombinant DNA technology in 
Escherichia coli. The side effects of intensive treatment include serious hypoglycemia, local 
reactions (swelling, erythema and stinging), allergy and edema. Newer insulin delivery 
devices have been made to improve ease and accuracy of insulin administration. These are 
insulin syringes, pen devices, inhaled insulin, insulin pumps, and implantable pumps (20). 
Review of Literature 
  
Institute of Pharmacology, MMC Page 17 
 
 
Type 
 
Zinc content 
Action ( hours) 
Onset peak Duration 
Rapid: 
a) Regular 
soluble 
 
b) Lispro 
Intermediate: 
a) NPH 
b) Lente 
Slow: 
a) Ultralene 
b) Protamine zinc 
c) Glargine 
 
 
0.01- 0.04 
 
0.02 
 
0.016 
0.2-0.25 
 
0.2-0.25 
0.2-0.25 
0.03 
 
 
0.5-0.7 
 
0.25 
 
1-2 
1-2 
 
4-6 
4-6 
2-5 
 
 
 
 
1.5-4 
 
0.5-1.5 
 
6-12 
6-12 
 
16-18 
14-20 
5-24 
 
 
5-8 
 
2-5 
 
18-24 
18-24 
 
20-36 
24-36 
18-24 
 
2) GLUCAGON LIKE PEPTIDE- 1 (GLP- 1) AGONIST: 
 The glucagon like peptide –1 (GLP-1) is an important incretin that is released from 
the gut in response to oral glucose. It is difficult to use clinically because of rapid degradation 
by the enzyme dipeptidyl peptidase-4 and it is injected subcutaneously twice daily one hour 
before meals acts for 6-10 hours. Nausea is an important side effect. 
3) AMYLIN AGONISTS: 
 This synthetic amylin (a polypeptide produced by pancreatic β-cells which reduces 
glucagon secretion from α-cells and delays gastric emptying) analogue attenuates 
postprandial hyperglycemia when injected subcutaneously just before meal and exerts a 
centrally mediated anorectic action. 
 
 
Review of Literature 
  
Institute of Pharmacology, MMC Page 18 
 
B) Oral hypoglycemic drugs: 
 Oral hypoglycemic drugs include sulfonyl ureas, biguanides, meglitinide 
/phenylalanine analogues, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase 
inhibitors and incretin mimetics. 
1) SULFONYL UREAS: [e.g. Glibenclamide, Glimepiride, Glipizide, etc.] 
 Sulfonyl ureas act primarily by increasing insulin secretion from pancreatic β-cells 
and cause hypoglycemia. Side effects include hypoglycemia, weight gain, allergic rashes and 
bone marrow damage. 
2) BIGUANIDES: [e.g. Metformin] 
 Metformin reduces blood glucose concentrations by increasing glucose uptake in the 
peripheral muscles and decreasing the amount of glucose produced and released in the liver 
i.e., suppress hepatic gluconeogenesis. Side effects include lactic acidosis, vitamin B12 
deficiency and gastrointestinal disturbances. 
3) MEGLITINIDE / D-PHENYLALANINE ANALOGUES: 
[e.g.Repaglinide, Nateglinide] 
 The glinides stimulates insulin secretion, although they bind to a different site within 
the sulfonylurea receptor. They have a shorter circulating half-life than the sulfonylurea must 
be administered more frequently. 
4) THIAZOLIDINEDIONES: 
 Thiazolidinediones are insulin sensitizers that increase insulin sensitivity and action in 
liver, muscle and fatty tissues to endogenous and exogenous insulin by binding and activating 
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the nuclear receptor peroxisome proliferator – activated receptor γ (PPAR-γ). Side effects 
include weight gain, fluid retention and GI disturbances. 
5) α-GLUCOSIDASE INHIBITORS :( e.g.Acarbose, Miglitol, Voglibose) 
 These drugs inhibit the action of intestinal disaccharidases enzymes that break down 
carbohydrates. These oral anti-diabetic agents delay glucose absorption. Side effects include 
flatulence, abdominal bloating and diarrhea. 
6) DIPEPTIDYL PEPTIDASE INHIBITORS :( e.g.Sitagliptin) 
 DPP-4 inhibitors increase insulin secretion and decrease glucagon level. It does not 
affect weight and does not induce hypoglycemia. Side effects include Gastro intestinal 
disturbances, headache, peripheral edema, and severe pain in upper stomach spreading to 
back. 
7) INCRETIN MIMETICS :( e.g.Liraglutide) 
 These drugs increase insulin secretion, suppress glucagon secretion and slows gastric 
emptying. Side effects include Gastro intestinal disturbances, headache, dizziness, asthenia, 
hypoglycemia, increase sweating and injection site reaction. 
ALTERNATIVE MEDICINES FOR DIABETES(22) 
 Insulin therapy is the only satisfactory approach in diabetes mellitus, even though it 
has several drawbacks like insulin resistance, anorexia, brain atrophy and fatty liver in 
chronic treatment. There are several oral hypoglycemic agents used therapeutically but 
certain adverse effects and weak effectiveness of them has led to the search for more 
effective agents. Therefore, herbal drugs are gradually gaining popularity in the treatment of 
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diabetes mellitus. The major qualities of herbal medicine seem to be their supposed efficacy, 
low incidence of serious adverse effects and low cost. 
MOST STUDIED AND COMMONLY USED ANTI DIABETIC 
MEDICINAL PLANTS 
Kumari et al., 1995,(23) 
                  Allium cepa (Onion) is an essential plant cultivated throughout India, belongs to 
the family Liliaceae.  Various parts such as seedling, callus, bulb etc., are known to possess 
anti-diabetic activity.  Investigations reveal the presence of sulfur containing amino acid, 
which when administered orally to alloxan-induced diabetic rats (200 mg/kg for 45 days) 
significantly controlled blood glucose and lipids in serum and tissues and normalized the 
activity of liver hexokinase, glucose-6-phosphatase and HMG-CoA reductase.  The effect 
was in accordance with that of glibenclamide and insulin. 
Zacharias et al., 1980.(24)  
                 Allium sativum (Garlic) belongs to the family of Alliaceae.  Aqueous extract of 
garlic increased hepatic glycogen, and free amino acid content when given orally to sucrose 
fed rabbits (10 ml/kg/day).  Garlic is known to decrease fasting blood sugar, triglyceride level 
in serum liver and aorta and protein levels when compared with sucrose controls. 
Faiyaz Ahmed and Asna Urooj, et al., 2008(25). 
                   The present investigation evaluated the antihyperglycemic activity of the bark 
powder and aqueous extract of Ficus glomerata (Moraceae) in streptozotocin induced 
diabetic rats.  Oral administration of bark powder (FGB) and aqueous extract (FGAE) at 500 
mg/kg caused 21% and 52% reduction in fasting blood glucose, respectively and also 
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decreased glycosuria significantly.  Histology of pancreas suggested normalization of islets of 
Langerhans and β-cells with respect to their number and cellular architecture.  The results 
suggest that, the bark of Ficus glomerata has significant anti-hyperglycemic activity in 
experimental animals and has potential to be used as an adjunct in the management of 
diabetes mellitus. 
M.R.M.Rafiullah and A.W.Siddiqui et al., 2006.(26) 
                The effect of aqueous extract of Syzygium cumini.Linn, Gymnema sylvestre (Retz) 
Schult and Portulaca olearacea.Linn were investigated in fasting normal and streptozotocin 
(STZ) induced diabetic rats.  The effects of extract on oral glucose tolerance in normal fasting 
rats were also studied.  The aqueous extracts of S.cumini (200 mg/kg) and G. sylvestre (200 
mg/kg) decrease the blood glucose in normal rats significantly at 2 and 4 hour of extracts 
administration (p < 0.05, p < 0.01).  The S. cumini and G.sylvestre extracts decrease the 
increase of glucose levels significantly (p < 0.05) at 90 and 180 minutes after the glucose 
load in glucose tolerance test.  In STZ induced diabetic animals, the aqueous extracts of 
S.cumini and G.sylvestre decrease the blood glucose significantly (p < 0.05) at 4 hour.  The 
aqueous extract of P.olearacea did not show any hypoglycemic activity. 
Rajasekaran et al., 2005.(27)   
               Aloe barbabensis, commonly called as Aloe vera is a medicinal herb; belongs to the 
family Liliaceae; Leaf gel, Leaf pulp and dried sap are known to possess anti-diabetic and 
anti-oxidant activity oral administration of ethanoloic extract at a concentration of 300 mg/kg 
body weight for 21 days, proved more effective in controlling oxidative stress found in 
diabetes. 
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 Gomes et al., 1995, Anderson and Polansky, 2002.(30) 
               Camellia sinensis belongs to the family Theaceae, commonly known as Tea.  The 
blood glucose level lowering activity has been extensively investigated.  Antihyperglycemic 
activity of hot water extract of green tea in STZ induced diabetic rats were studied by Gomes 
et al.(1995), these findings have been supported by Anderson and Polansky(2002). Tea 
polyphenols possess antioxidant capacity; have also been reported to inhibit α-amylase. 
AVAILABLE STUDIES ON Portulaca quadrifida Linn. 
Syed kamil M et al., 2010.(31)  
 The effect of ethonalic extract of Portulaca quadrifida Linn.were studied in mice 
using various models.  The effect of ethonalic extract of Portulaca quadrifida Linn.on central 
and peripheral nerves system were studied by using spontaneous motor activity, anti-
nociceptive activity, in vivo muscle relaxants activity (grip strength) and anti-convulsant 
activity.  The extract (400 and 800 mg/kg i.p) showed a significant reduction in spontaneous 
motor activity, antinociceptive activity and also showed reduction in time to recover from the 
electrically induced convulsion.  The effect of extract on grip strength was found non-
significant.  Results from the present study indicate that Portulaca quadrifida Linn. has 
significant effect on central nerves system but not on peripheral nerves system. 
Patil AG, Patil DA et al., 2012(32) 
 The herbal products today symbolize safety in contrast to synthetic drugs that are 
regarded unsafe to the human and environment. Portulaca quadrifida Linn. a traditional 
medicinal plant, valued for its benefits in the management of urinary and inflammatory 
disorders. The decoction of plant acts as anthelmintic and used in the treatment of stomach 
complaints and gonorrhea. The powder microscopy showed the presence of tannins, 
mucilage, steroidal compounds and carbohydrates. 
Syed kamil mulla and Paramjyothi swami, 2012(33) 
 Portulaca quadrifida Linn. (Portulacaceae) is traditionally used for the treatment 
against various ailments in tropical and sub-tropical parts of India without any scientific 
knowledge. Polyphenols, present in different fruits and vegetables, have retained attention in 
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recent years. In the present study the effects of ethanol and polyphenol extracts of Portulaca 
quadrifida Linn. on the proliferation of human colon cancer HT-29 and a normal L-6 cell 
lines were investigated by MTT assay and Trypan blue dye exclusion assay followed by 
DNA fragmentation assay. The results confirm that the ethanolic and polyphenolic extracts 
exhibited fragmentation of DNA in HT-29 cell lines and are found less effective against 
normal L-6 cell lines indicating the cancer specific effect of Portulaca quadrifida Linn. 
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PLANT PROFILE(29) 
 
Name    : Portulaca quadrifida L.  
 
Synonym   : Portulaca anceps A.Rich 
      
     Portulaca geniculate Royle 
TAXONOMY 
 
Kingdom    : Plantae 
 
Phylum    : Magnoliophyta 
 
Class     : Magnoliatae 
 
Order    : Caryophyllales 
 
Genus    : Portulaca 
 
Family    : Portulacaceae  
 
Vernacular names  :          English  - chickenweed  
 
           Tamil  - Siru pasalai, Tharai pasalai  
 
 Sanskrit -   Paciri, Paviri 
  
 Telugu  -  Goddu paveli 
  
 Malayalam -   Neelakeera  
   
     Others  -     Lunki buti, Pulikeerai 
 
Habitat                        :         Arenosol, subtropical, tropical, prostrate herb, upto 20cm. 
 
 
Distribution   :         Pan tropical, Common in tropical India and Africa, U.S.                 
 
              Virgin Islands and Asia. 
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Portulaca Quadrifida L. – FLOWER 
 
 
 
WHOLE PLANT 
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Description  
 
The plant:  
 
A small diffused succulent, annual herb/forb. Stem is rooting at the nodes. The  
 
diameter of stem was found to be 0.1 cm.  
 
Leaves:  
 
 Leaves are opposite, fleshy, ovate, acute apex, entire margin; stipulate  
 
with a ring of silvery hairs. 
 
 The length of leaf is about 0.9 cm, and breadth is about 0.3 cm. 
 
Flowers: 
 
 Flowers are small, Dicot, terminal, and solitary, surrounded by a 4-leaved  
 
involucre and copious white hair.  
 
 Petals are four and yellow in colour. 
 
Capsule: 
 
  Capsule dehisces horizontally, and contains minutely tubercled seeds. 
 
Chemical composition:  
 
Alkaloids, glycosides, mucilage, 
 
Tannins, proteins, flavonoids,  
 
Saponins, carbohydrates, triterpenoids 
 
Parts used: 
 
Whole plant. 
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Properties and Use: 
 
 Portulaca quadrifida L. is used as a laxative. 
 
 It cures fevers, asthma, cough and urinary disorders. 
 
 Good for eye diseases, skin diseases and ulcers. 
 
 Leaves are used as a local application to swellings. 
 
 Portulaca quadrifida L. has been reported to possess antifungal activity  
 
against Aspergillus fumigates and Candida albicans.(31) 
 
 It has a significant effect on central nervous system.(30) 
 
 It has anticonvulsant activity and anticancer activity.(32) 
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STUDY DESIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portulaca quadrifida L. 
Authentication of plant material 
Collection and processing of plant 
Extraction with Ethanol 
Phytochemical studies Pharmacological studies 
Invivo study Invitro studies 
1. Glucose diffusion assay 
2. Glucose adsorption assay 
• Blood glucose and 
body weight changes. 
• Haematological & 
Biochemical 
parameters. 
• Tissue homogenate-
Estimation of 
Lysosomal enzymes, 
Carbohydrate 
metabolizing enzymes. 
• Histopathological study 
Acute toxicity study 
(OECD Guidelines 423) 
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MATERIALS AND METHODS 
PLANT COLLECTION AND IDENTIFICATION 
  Dried entire plant of Portulaca quadrifida L. was collected from the forest 
around Komaneri, Tuticorin district, Tamilnadu (INDIA), in the month of July. It was 
authenticated by Prof. V. Chelladurai, Research Officer- Botany (Scientist - C) (Rtd), Central 
Council for Research in Ayurveda & Siddha, Govt. of India. 
PREPARATION OF PLANT EXTRACT 
  The powdered plant material (50 g) was extracted by hot continuous soxhlet 
extraction method. The plant material was extracted with ethanol (99.9% v/v) (500 ml) for 2 
days in a percolator.  
  It is a process of continuous extraction method in which the solvent can be 
circulated through the extractor for several times. The vapours from the solvent are taken to 
the condenser and the condensed liquid is returned to the extract for continuous extraction. 
The apparatus consist of body of extractor (thimble) attached with side siphon tube, lower 
end attached with distillation flask and the mouth of extractor is fixed to the condenser by the 
standard joints. 
Procedure:  
 Weighed about 50g of dried powdered plant and transferred into thimble for packing. 
 While packing, the content was wetted with ethanol (99.9% v/v) and then poured until 
the siphon tube was filled. 
 A piece of porcelain was added into the round bottom flask to avoid bumping effect. 
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solution to second portion and the gelatin salt reagent to third portion. Precipitation with the 
latter reagent or with both the gelatin salt reagent was indicative of the presence of tannins. 
Precipitation of salt solution indicated a false-positive test. Positive tests were further 
confirmed by the addition of a few drops of dilute ferric chloride (1% FeCl3) to test extracts, 
which gave black or green colouration. 
 The extract was mixed with lead acetate solution and observed for white precipitate. 
4. Test for saponins: 
• Foam test: A small amount of extract was extracted with petroleum ether. To the 
insoluble residue left after extraction, a few ml of water was added and shaken 
vigorously for 15 minutes and was observed for the formation of honeycomb froth 
that persisted for at least 30 minutes. 
5. Test for terpenoids: 
• Noller’s test: The extract was warmed with tin and thionyl chloride. Pink colouration 
indicates the presence of terpenoids. 
6. Test for glycosides: 
• Borntrager’s test: A small amount of extract was hydrolyzed with hydrochloric acid 
for few hours on a water bath and the hydrolysate was extracted with benzene. The 
benzene layer was treated with dilute solution and was observed for formation of 
reddish pink colour. 
• Legal test: the extract was dissolved in pyridine and was made alkaline with few 
drops of 10% sodium hydroxide and then freshly prepared sodium nitroprusside was 
added and observed for the formation of blue colour. 
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7. Test for phytosterols: 
• Libermann – Burchard test: 1 mg of the extract was dissolved in few drops of 
chloroform, 3 ml of acetic anhydride and 3 ml of glacial acetic acid. Warmed, cooled 
under tap water and drops of concentrated sulphuric acid was added along the side of 
the test tube, formation of bluish green colour indicates the presence of steroids. 
DRUGS AND CHEMICAL 
  Sodium Chloride, D- glucose, Ethanol, Sodium citrate tribasic-dehydrate, 
Citric acid monohydrate, Streptozotocin, Glibenclamide. 
II) IN VITRO ANTIDIABETIC EVALUATION  
PHYSICAL METHOD 
   Ability of the plant materials to retard the movement of glucose from the 
intestine into the blood was evaluated by physical methods in vitro, because the absorbed 
glucose from the intestine will cause the rise in postprandial hyperglycemia (PPHG) which 
complicates the diabetic condition associated with risk factors. The following are the 
convenient models for assessing the materials which affect the absorption of glucose in vitro. 
A. GLUCOSE DIFFUSION ASSAY(33): 
Plant extracts were mixed with glucose and placed in the sealed dialysis membrane 
and kept, and in the orbit shaker bath at 37º C, at 150rpm, and the movement of glucose 
across the membrane into the external solution was measured at periodic intervals using 
commercial GOD-POD kit. 
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REQUIREMENTS: 
o Dialysis membrane 
o 0.15 M Sodium chloride solution 
o D- (+) – Glucose  - (25Mm in sodium chloride solution) 
o Orbit shaker 
o GOD – POD kit 
PROCEDURE: 
 Dialysis membrane containing 2 ml of 25mM glucose solution was mixed with 1ml of 
different concentrations of plant extracts (100, 250,500,1000 and 1500µg/ml) and was placed 
in the centrifuge tube containing 45ml 0.15M NaCl and then kept in orbit shaker bath at 
37ºC,at 150rpm.  The movement of glucose into the external solution was monitored at 0, 1, 
2, 3, 4, 5 hours using GOD-POD kit.  Glucose concentration in the external solution was 
expected as mg/dl/hr. 
B.GLUCOSE ADSORPTION ASSAY(34) 
Principle  
 Glucose binding ability of the plant materials was determined by the method of   Ou 
et al., 2001. Plant extract samples were incubated for 6 hours with various concentrations of 
glucose and the free glucose concentration at the end of the incubation period was determined 
using GOD-POD kit. 
 
 
Materials and Methods 
  
Institute of Pharmacology, MMC Page 34 
 
Sample (1%w/v) + Glucose solution (conc. In mM)        incubated at 37°C for 6 hours         Centrifuged 
             
      Glucose in supernatant was measured 
Requirements 
o Glucose solution (D-(+)-Glucose in various concentrations in distilled water) 
o GOD-POD kit 
o Orbit shaker bath 
Procedure 
 Plant extracts (1%) were mixed with 25ml of glucose solution of increasing 
concentration (5, 10, 25, 50 and 100 mM) and incubated in the orbit shaker bath at room 
temperature for 6 hours, centrifuged at 4000 rpm for 20 minutes and the glucose content in 
the supernatant was determined by using the GOD-POD kit. Glucose bound was calculated 
using the formula: 
     G0  -  G6 
Glucose bound (nm) = x Vol. of the solution (ml) 
       Weight of the sample (mg) 
       
  
Where, G0 – glucose concentration at ‘0’ hours expressed as mg/dL 
 G6 – glucose concentration at ‘6’ hours expressed as mg/dL 
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III) IN VIVO ANTI DIABETIC STUDIES 
Experimental Animals: 
The present study was conducted after obtaining approval from the Institutional Animal 
Ethics Committee and this protocol met the requirements of national guidelines of CPCSEA 
(PROPOSAL NO: IAEC 13/243/CPCSEA). The Wistar albino rats (150-200 gm) used for 
this study were procured from Animal house, Madras Medical College, Chennai, India. 
Quarantine and Acclimatization: 
Quarantine is the separation of newly received animals from those already in the facility 
until the health and possibly the microbial status of the newly received animals have been 
determined. The newly procured Wistar albino rats were quarantined for the period of one 
week to minimize the chance of introduction of pathogens into established animals and 
allowed to develop the psychological, physiological and nutritional stabilization before their 
use.  
Housing: 
The animals were housed in well ventilated animal house which was maintained at a 
constant temperature and relative humidity of 55 to 60%. The animals were housed in 
spacious polypropylene cages and paddy husk was utilized as bedding material. 
Diet and water: 
The animals were maintained on standard pellet diet and purified water. The animals 
were provided with food and water ad libitum except during fasting. The bed material was 
changed twice a week. 
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Animal identification: 
All animal cages used in the study had a proper identification i.e., labels. Each animal 
in the cage was marked either on head or body or tail with picric acid for their appropriate 
identification 
A) TOXICITY STUDIES: 
Acute toxicity was designed as per the OECD guidelines (423).(37) 
ACUTE TOXICITY STUDY: 
Principles and purpose: 
The main purpose of acute toxicity is to evaluate the degree of toxicity in a 
quantitative and qualitative manner with the purpose of comparing it with other drug 
substances (e.g. other drug candidates for the same indication). 
Experimental Animals: 
 Three healthy adult Wistar albino rats weighing between 150-250g were selected for 
the study.  For all the three animals food, but not water was withheld overnight prior to 
dosing. 
Selection of dose levels and administration of doses: 
Being a traditional herbal medicine, the mortality was unlikely at the highest starting 
dose level (2000mg/kg body weight).  Hence a limit test at one dose level of 2000mg/kg body 
weight was conducted in all the three animals. 
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B) INVIVO ANTIDIABETIC EVALUATION: 
 The antidiabetic activity of Portulaca quadrifida Linn was evaluated in diabetic 
Wistar rats. Diabetes was induced by intra-peritoneal injection of Streptozotocin 50mg/kg 
body weight. The antidiabetic effect of plant extract was compared with standard drug 
Glibenclamide. 
(i) Induction of diabetes in rats: 
After a week of acclimatization, the rats were subjected to overnight fasting. Diabetes 
was induced by intraperitoneal injection of Streptozotocin, freshly dissolved in citrate buffer 
pH 4.5. The animals were allowed to drink water 5% glucose solution overnight to overcome 
the drug induced hypoglycemia due to massive release of insulin from β-cells. After 3 days, 
blood glucose levels were measured and the animals with a blood concentration of more than 
250 mg/dl were considered as diabetic and taken for the experiment. Administration of the 
plant extract was started on the 4th day after streptozotocin injection and this was considered 
as the 1st day of treatment, which was continued for 21 days. 
(ii)Experimental design: 
The fasting glucose and body weight of all animals were recorded at the beginning of 
the study.  The blood glucose was checked by one – touch glucometer throughout the study, 
in the experiments, 24 rats were divided into 4 groups of six rats each. 
GROUP 1: Normal control rats, received distilled water. 
GROUP 2: STZ induced diabetic rats received distilled water and served as diabetic 
control for 21 days. 
GROUP 3: STZ induced diabetic rats received standard drug Glibenclamide (5mg/kg BW 
p.o) for 21 days. 
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GROUP 4: STZ induced diabetic rats received the plant extract (200mg/kg BW p.o) for 
21 days. 
GROUP 5: STZ induced diabetic rats received the plant extract (400mg/kg BW p.o) for 
21 days 
  For all rats, body weight was measured before the induction of diabetes (-4th day) and 
on 7, 14 and 21st day of the treatment. Blood glucose level was measured on 1, 7, 14 and 21st 
days throughout the study period by tail tip cutting method. At the end of the experiment on 
21st day, sufficient blood was collected by retro-orbital bleeding from all the animals under 
anaesthesia for estimation of haematological and biochemical parameters. 
(iii) Biochemical parameters 
The blood samples were centrifuged at 3000rpm for 5 minutes using REMI (412 
LAG) cooling centrifuge. The serum was kept at -80°C until analyzed. Levels of serum 
glutamate oxaloacetic transaminase (SGOT), serum glutamate pyruvic transaminase (SGPT), 
serum alkaline phosphatase (ALP), serum creatinine, urea, total cholesterol, triglycerides 
(TGL), HDL and total protein were determined with an automatic analytical instrument 
(Hitachi 911, Japan). 
A.ESTIMATION OF TOTAL PROTEIN (Biuret Method)(38) 
 The serum content of the soluble proteins, those circulating in extracellular and 
intracellular fluids, has been used as a marker to aid in clinical diagnosis. Serum total protein 
including albumin is mainly involved in the maintenance of normal water distribution 
between tissues and the blood and responsible for maintaining the osmotic pressure of plasma 
and is used to transport many substances including macromolecules. 
Principle 
 In the biuret reaction, a chelate is formed between the Cu2+ ion and the peptide bonds 
of the proteins in alkaline solutions to form a violet coloured complex whose absorbance is 
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measured photometrically. The intensity of the colour produced is proportional to the 
concentration of the protein in the sample. 
 Cu2+ + Serum protein    Copper-protein complex 
Reagents 
 Biuret reagent  
 1ml of protein standard 
 Serum sample 
Procedure 
 1ml of biuret reagent which is stored under 2-8°C and 10µl of serum sample/standard 
are mixed well and then it is incubated for 5 mins. The intensity of the colour is measured at 
540 nm. 
Calculation 
Absorbance of test 
Total protein in gm/dL =       X 5.5   
Absorbance of standard 
B.ESTIMATION OF LIPID PROFILE(39) 
Principle 
            The cholesterol esters and cholesterol present in the sample are acted upon by 
Cholesterol Esterase to release Cholesterol and Fatty acids. The Cholesterol is oxidized by 
Cholsterol Oxidase to yield 4-Cholesten 3-one and Hydrogen peroxide as by product. 
Hydrogen peroxide together with 4-aminoantipyrin and phenolic compound in the presence 
of peroxidase gives the coloured complex. The intensity of the colour is proportional to the 
total cholesterol in the sample and is measured at 550 nm or with Green filter. 
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Cholesterol ester + H2O Cholesterol Esterase  cholesterol + Fatty acids 
Cholesterol +O2 cholesterol oxidase        4-Cholesten-3-one-H2O2 
2H2O2 + Phenol + 4-aminoantipyrine   peroxidase    Red quinone + 4H2o 
Requirements 
 Enzyme reagent 
 HDL ppt reagent 
Procedure 
 1ml of enzyme reagent and 10µl of test/standard were mixed well and incubated at 
37°C for 5mins. The absorbance of test and standard were measured at 505 nm or using 
Green filter. 
Calculation  
     Absorbance of test  
Cholesterol conc. mg/dl     =      x Conc. of Standard (200) 
     Absorbance of standard 
HDL Cholesterol(40): 
Procedure  
Step 1:  
 200µl of serum and 300 µl of HDL ppt reagent were mixed well and allowed to for 
10mins. Then the mixture was centrifuged at 3000rpm for 10mins and the supernatant was 
separated. 
Step 2: 
 1ml of enzyme reagent and 100 µl of supernatant from step A were mixed together 
and incubated for 5mins at 37°C. The absorbance is read at 505 nm. 
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Calculation 
     Absorbance of test  
HDL Cholesterol conc. mg/dl   =       x Conc. of Standard (50) 
     Absorbance of standard 
TRIGLYCERIDE(41) 
 In human nutrition, triglyceride is the most prevalent glycerol esters encountered. 
They constitute 95% of tissue storage fat are the predominant form of glycerol ester found in 
plasma. The investigation of triglyceride is part of the overall evaluation of lipids disorders. 
Principle 
 Triglyceride + H2O                     LPL   Glycerol + free fatty acid 
 Glycerol + ATP       GK  Glycerol-3-phosphate + ADP 
 Glycerol-3-phosphate + O2 GPO       DAP + H2O2 
 
H2O2 + 4AAP + 3, 5-DHBS      Peroxidase  Quinoeimine Dye + 2H2O2 
Requirements 
 Pipes buffer pH 7.0 
 4-AAP 0.4mmol/l 
 Magnesium 2mmol/l 
 ATP 2mmol/l 
 GK 
 POD 
 LPL 
 GPO 
 Surfactants 
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Procedure 
 1ml of reagent mixed with 10 µl of sample and incubated for 5min at 37°C.Then the 
absorbance is measured at 505 nm. 
Calculation 
 Triglyceride mg/dl =  Ax/As x Concentration of Standard 
Where, Ax – absorbance of sample, As- absorbance of standard 
C. ESTIMATION OF UREA(41) 
 Urea is the end product of the protein metabolism. It is synthesized in liver from the 
ammonia produced by the catabolism of ammonia acids. It is transported by the blood to the 
kidneys from where it is excreted. Increased levels are bound in renal diseases, urinary 
obstructions, shock, congestive heart failure and burns. Decreased levels are found in liver 
failure and pregnancy. 
Principle:  
Urea is an acidic medium condenses with Diacetyl monoxime at 100oc to form a red 
coloured complex. Intensity of the colour formed is directly proportional to the amount of 
urea present in the sample. 
 Urea + H2O Urease    2NH3  +    CO2 
 Urea + Diacetyl monoxime ------------------ Red Coloured Complex 
Contents:    25 ml    75 ml 
L1: Urea Reagent   75 ml    150 ml 
L2: Acid Reagent   75 ml    150 ml 
L3: DAM Reagent   75 ml    150 ml 
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S: Urea Standard (40 mg/dl)  5 ml    5 ml 
Procedure 
Addition sequence Blank (B) ml Standard (S) ml Test (T) ml 
Urea reagent (L1) 
Acid reagent (L2) 
DAM reagent 
Distilled water 
Urea Standard (S) 
Sample 
1.0 
1.0 
1.0 
0.01 
- 
- 
1.0 
1.0 
1.0 
- 
0.01 
- 
1.0 
1.0 
1.0 
- 
- 
0.01 
 
 Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test (T). 
Mix well and keep the test tubes in boiling water (100oc) for 10min. Cool under running tap 
water and measure the absorbance of the standard (Abs. S), and Test sample (Abs. T) against 
the blank. 
 
Calculation 
Abs. T 
Urea in mg/ dl   = ----------------------- X 40 
     Abs. S  
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D. ESTIMATION OF CREATININE(41) 
 Creatinine is a waste product formed from creatine phosphate, a high energy storage 
compound. It is removed from plasma by glomerular filtration and then excreted in urine. 
Creatinine is a useful indicator of renal function. 
 Elevated levels of creatinine are associated with abnormal renal function as it  relates 
to glomerular filtration. 
 Serum creatinine levels are used in combination with Urea/BUN to differentiate 
between pre-renal and renal causes of azotemia (condition of increased BUN level) 
Principle 
 Creatinine reacts with picric acid in alkaline environment to form an orange-red 
colour complex. Developing of this orange-red colour may be followed photometrically at 
500-520 nm. 
 Creatinine + Picric acid  NaOH  orange-red formation 
Requirements 
 Picric acid 11mmol/l 
 NaOH 0.3mmol/l 
 Creatinine standard 
Procedure 
 1ml of reagent and 100µl of sample/standard are mixed and incubated for 60seconds 
at 37°C. Then the absorbance (A1) measured at 505 nm. After exactly 60second absorbance 
(A2) was measured. 
Calculation 
 Creatinine mg/dl = A2 – A1(sample)/ A2 – A1(standard) x concentration of standard 
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E.ESTIMATION OF ASPARTATE AMINOTRANSFERASE (AST/ SGOT)(42) 
 Aspartate transaminase (AST) also referred to serum glutamate oxaloacetate 
transferase (SGOT) is an enzyme involved in amino acid metabolism. AST is widely 
distributed in liver, RBCs, heart, pancreas and kidney. Low level of SGOT in blood is 
observed in severe liver disease, myocardial infarction, heart failure, kidney disease and lung 
disease. 
Principle 
 α-Ketoglutarate + L-Aspartate SGOT  L-Glutamate + Oxaloacetate 
 Oxaloacetate + NADH+ H+       MDH  L-Malate + NAD+ 
 The rate of NADH consumption is measured photometrically and is directly 
proportional to the SGOT concentration in the sample. 
Reagents  
 L-Aspartate  >200mmol/l 
 Malate dehydrogenase > 200mmol/l 
 α-Ketoglutarate >35mmol/l 
 NADH >1.05mmol/l 
Procedure 
 800µl of L-Aspartate & Malate dehydrogenase and 200µl of α-Ketoglutarate are 
mixed together and incubated at 37°C for 2 minutes and 100µl of sample is added. The 
change in absorbance is measured at 340 nm. 
Calculation 
AST  = ∆Abs/ min  x Factor (1746) 
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F.ESTIMATION OF ALANINE AMINOTRANSFERASE (ALT/ SGPT)(43) 
 Alanine aminotransferase / serum glutamate pyruvate transferase is an enzyme 
involved in amino acid metabolism. 
Principle 
 α-Ketoglutarate + L-Alanine SGPT  L-Glutamate + Pyruvate 
 Pyruvate + NADH+ H+       LDH  L-Lactate + NAD+ 
 The rate of NADH consumption is measured photometrically and is directly 
proportional to the SGPT concentration in the sample. 
Reagents  
 L-Alanine  >200mmol/l 
 Lactate dehydrogenase > 1500mmol/l 
 α-Ketoglutarate >35mmol/l 
 NADH >1.05mmol/l 
 Tris buffer 80mmol/l pH 7.5 
Procedure 
 800µl of L-Alanine & Lactate dehydrogenase and 200µl of α-Ketoglutarate are mixed 
together and incubated at 37°C for 2 minutes and 100µl of sample is added. The change in 
absorbance is measured at 340 nm. 
Calculation 
ALT  = ∆Abs / min  x Factor (1746) 
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(iv) Estimation in tissue homogenates 
A) PREPARATION OF TISSUE HOMOGENATE 
 At the end of 21st day, all the experimental animals were sacrificed and liver, pancreas 
and kidney were removed, free from adhering tissues and washed with ice-cold normal saline 
solution (0.9%). About 0.3g tissue was homogenized in 3ml of 0.01 M Tris-HCl with the help 
of Teflon-homogenizer. The homogenate was centrifuged at 10,000 rpm for 20mins at 4°C. 
The supernatant obtained was used for estimation of lysosomal enzymes and some 
carbohydrate metabolizing enzymes 
B) CARBOHYDRATE METABOLIZING ENZYMES ESTIMATION 
1) HEXOKINASE ESTIMATION(44) 
Principle 
 Hexokinase (HK) activity was determined by the method of Brandstrup et al., (1957). 
The assay is based upon the reduction of NAD+ through a coupled reaction with glucose-6-
phosphate dehydrogenase and is determined spectrophotometrically by measuring the 
increase in absorbance at 340nm. 
D-Glucose + ATP      hexokinase            Glucose-6-phosphate + ADP 
Glucose-6-phosphate        2P   Gluconate-6-phosphate + NADH+H+ 
 One unit of activity reduces one micromole of NAD+/min at 30°C and pH 8.0 under 
the specified conditions. 
Reagents 
 0.05M Tris-Hcl buffer, pH8.0 with 13.3mM MgCl2 
 0.67M Glucose in above Tris-MgCl2 buffer 
 16.5mM Adenosine 5’Triphosphate in above Tris-MgCl2 buffer 
 6.8mM NAD in above Tris-MgCl2 buffer 
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 Glucose -6-phosphate dehydrogenase (G6PD) 
Procedure 
 The assay mixture containing 2.28 ml of Tris-MgCl2 buffer, 0.5 ml of 0.67M Glucose, 
0.1 ml of 16.5mM ATP, 6.8mM NAD and 0.01 ml of G6PD was mixed well. To the above 
mixture 0.1ml of tissue homogenate was added and the increase in absorbance was measured 
at 340nm for 5minutes. 
2) ESTIMATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD)(45) 
Principle 
 G6PD activity was estimated by the method of Anderson & Nordlie et al., (1968). 
This G6PD is rather unique in that it possesses dual coenzyme specificity. When assayed 
under conditions that are optimal for the particular coenzyme, the ratio of observed catalytic 
activity is NAD/NADP = 1.8. The reaction velocity is determined by measuring the increase 
in absorbance at 340nm resulting from the reduction of NAD or NADP. 
Reagents 
 0.055M Tris-HCl buffer pH 7.8 containing 0.0033 M Magnesium Chloride 
 0.06M Nicotinamide Adenine Dinucleotide (NAD) 
 0.1M Glucose-6-phosphate 
 G6PD enzyme 
Procedure 
 The assay mixture containing 2.7 ml of 0.055M Tris-HCl buffer, pH7.8 with 0.0033M 
MgCl2, 0.1ml of 0.06M NAD and 0.1 ml of Glucose-6-phosphate. 0.1 ml of tissue 
homogenate was added to the above assay mixture and the change in absorbance was 
measured at 340nm for 5mins 
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3) LACTATE DEHYDROGENASE (LDH) ASSAY(46) 
Principle 
 The assay was performed according to King’s et al., (1965) method, when the enzyme 
is supplied with Pyruvate and NADH+, the LDH catalyzed reaction starts to produce lactate. 
At certain time point the reaction is terminated by the addition of 2,4- 
Dinitrophenylhydrazine, which reacts with lactate at acidic pH
.  
After 
 
alkalization (addition 
of NaOH) the resulting hydrazine derivate gives a yellowish-orange colour suitable for 
quantification by means of spectrophotometry at the wavelength of 440 nm. 
Requirements 
 0.1M phosphate buffer (pH 7.5) 
 NADH(6.6mM) 
 Sodium pyruvate (30mM) 
 Dinitro phenyl hydrazine 
Procedure 
 0.1ml of tissue homogenate was added with 2.7 ml buffer, 0.1ml NADH, and 0.1ml 
sodium pyruvate. The mixture was heated for 15 mins at 37°C. Then 0.5ml of dinitro phenyl 
hydrazine was added and incubated at room temperature for 15 mins. The reaction was 
stopped by addition of 5ml 0.1N NaOH. The developed colour was measured at 440nm. 
C.LYSOSOMAL ENZYMES ESTIMATION IN TISSUE PREPARATIONS 
1) ASSAY OF ALKALINE PHOSPHATASE (ALP)(47) 
Principle 
 When the enzyme incubated with p-Nitro phenyl phosphate and Tris buffer (pH 9.6), 
in alkaline condition inorganic phosphate and p-Nitro phenol are formed by the catalytic 
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action of alkaline phosphatase. Amount of p-nitro phenol liberated by the enzyme is 
measured at 420 nm. 
2-amino-methyl-1-propanol + p-Nitro phenyl phosphate + H2O 
 
 
4-Nitro phenol + 2-amino-2-methyl-1-propanol phosphate 
Requirements 
 P-nitro phenyl phosphate (10 mM) 
 Tris-HCl pH 9.6 (80mM) 
 NaOH (0.1N) 
Procedure 
 1ml of p-nitro phenyl phosphate and 1.5 ml of buffer were added with 100µl of 
homogenate. The mixture was incubated at 37°C for 30mins. Then the reaction was stopped 
by addition of 0.1 N NaOH. The absorbance of liberated p-nitro phenol was measured at 
420nm. 
Calculation  
 ALP U/I = ∆A/ 2764 
2) ASSAY OF ACID PHOSPHATASE (ACP)(48) 
(α-Naphthylphosphate Kinetic method) 
Principle 
 In acidic condition, the incubation of α-Naphthylphosphate with ACP will liberate α-
Naphthol and inorganic phosphate due to catalytic action of ACP. The α–Naphthol is coupled 
with Fast Red to form a diazo dye complex. The rate of formation of this complex is 
measured as an increase in absorbance which is proportional to the ACP activity in the 
sample. 
α –Naphtholphosphate + H2O ACP     α –Naphthol + Phosphate 
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α –Naphthol + Fast Red TR Salt   Diazo dye complex 
 
Requirements 
 α –Naphthol phosphate (4.5mM) 
 acetate buffer (pH5.0) 
 NaOH (0.2N) 
Procedure 
 1ml of α –Naphthol and 1.9 ml of buffer were added with 100µl of homogenate. The 
mixture was incubated at 37°C for 30mins. The absorbance of liberated α–Naphthol was 
measured at 420 nm. 
Calculation  
 ACP activity in U/L = ∆A/min x 750 
HISTOPATHOLOGICAL STUDIES: 
At the end of 21st day, all the animals were sacrificed to collect the pancreas and liver.  
The organs were rinsed in ice cold 0.9% saline and were fixed in 10% formalin embedded in 
paraffin and cut into 5 µm thick sections in a microtome.  Sections were mounted on glass 
slides using standard techniques.  After staining with Hematoxylin-Eosin, the sections were 
examined under 100X magnification and photographed under a light microscope equipped 
for photography (Olympus CK 40).   
STATISTICAL ANALYSIS: 
All the parameters were analysed by ANAVO followed by Dunnet’s test.  The results 
were expressed as Mean ± SD.  The statistical analysis was performed by using Graph and 
Prism, version 6.0 software. 
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PRELIMINARY PHYTOCHEMICAL ANALYSIS 
 
TEST 
 
RESULTS 
Test For Flavonoids 
a) Shinado’s test 
b) Sodium hydroxide test 
 
Present 
Present 
Test For Tannins 
With lead acetate 
 
Present 
Test For Saponins 
Foam test 
 
Present 
Test For Tepenoids 
With Tin and thionyl chloride 
 
Present 
Test For Glycosides 
a) Libermann-burchard’s test 
b) Legal’s test 
c) Borntrager’s test 
 
Present 
Present 
Present 
Test For Phytosterols 
Libermann test 
 
Present 
Test For  Mucilage 
Swelling test 
 
Present 
Test For Protein 
a) Biuret test 
b) Million’s test 
 
Present 
Present 
Test For Carbohydrates 
Molish’s test 
 
Present 
Test For Alkaloids 
a) Drangendroff’s test 
b) Mayer’s test 
c) Hager’s test 
d) Wagner’s test 
 
Present 
Present 
Present 
Present 
 
Table shows the preliminary phytochemical analysis of ethanolic extract of  Portulaca 
quadrifida L.  
Results 
  
Institute of Pharmacology, MMC Page 54 
 
TOXICITY STUDIES 
ACUTE TOXICITY STUDY: 
The crude ethanolic extract of Portulaca quadrifida L. was subjected to acute toxicity study. 
 
 
S.NO. 
 
 
PARAMETERS 
 
RESULT 
 
1. Toxic signs Absent 
2. Pre-terminal deaths Nil 
3. Body weight No specific change 
4. Cage side observation Normal 
5. Motor activity Normal 
6. Tremors Absent 
7. Convulsions Absent 
8. Straub reaction Absent 
9. Pilo erection Absent 
10. Righting reflex Present 
11.  Lacrimation and salivation Normal 
12. Unusual vocalization Absent 
13. Sedation Absent 
14. Body temperature Normal 
15. Analgesia Absent 
16. Ptosis Absent 
17. Diarrhea Absent 
18. Skin colour Normal 
19. Respiration Normal 
20. Scratching Absent 
21. Grooming Absent 
22. Aggressiveness and restlessness Absent 
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Animals were observed for behavioral signs of toxicity like motor activity, tremor, 
ect., and no significant toxic signs were observed during 14 days. The results of the acute 
toxicological studies revealed that the administration of ethanolic extract of Portulaca 
quadrifida L. by oral route upto 2000mg/kg body weight did not produce any mortality and it 
was tolerated. 
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Table 2          GLUCOSE ADSORPTION ASSAY 
 
 
 
 
 
 
 
 
 
Table 2 shows the glucose adsorption capacity of PQ extract at 1% concentration, values 
expressed as mean glucose bound (nm) with SD. 
 Glucose solution in a concentration of 50mM showed maximum glucose adsorption of 53 nm, 
at 100mM concentration the value was reduced to 27 nm. 
Figure 1     GLUCOSE ADSORPTION ASSAY             
 
Figure 1 shows the graphical representation of mean glucose adsorption 
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Table 3  GLUCOSE DIFFUSION ASSAY 
Concentration 
(µg/ml) 
Glucose concentration (mg/ml) 
0 hour 1
st
  hour 2
nd
 hour 3
rd
 hour 4
th
 hour 5
th
 hour 
100 2.48±0.08 
 
33.69±1.44 44.44±1.69 43.54±0.49 47.37±1.13 66.83±2.23 
250 2.79±0.02 
 
32.02±1.75 41.9±2.52 45.07±1.26 45.96±2.07 54.76±0.81 
500 2.41±0.01 
 
27.93±1.34 38.2±1.03 42.1±1.12 443.2±2.81 50.63±1.52 
1000 2.54±0.04 
 
25.63±0.93 30.7±0.70 34.9±0.91 39.37±0.61 44.83±2.21 
1500 2.43±0.17 
 
23.63±0.82 25.63±0.52 27.1±1.39 34.1±4.06 33.37±1.44 
Control 
(0 µg/ml) 
3.16±0.34 
 
35.37±1.15 47.3±0.4 53.57±0.49 58.87±1.59 73.57±2.16 
 
Table 3 shows the mean glucose intensity in the external solution of various 
concentrations of PQ at different time intervals. Glucose values are expressed as Mean 
± SD 
PQ extract decreased the concentration of glucose into the external solution by 
retarding its diffusion through membrane. After 5 hrs the control showed 73.57 mg/dl of 
glucose in the external solution whereas the PQ extract at 1500µg/ml showed only 33.3 mg/dl 
of glucose. PQ extract possesses a dose dependent effect in glucose diffusion and it showed 
highest activity at concentration of 1500µg/ml.  
 
Figure 2 is the graphical representation of Table 
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INVIVO ANTIDIABETIC ACTIVITY 
Table 4:  Effect of ethanolic extract of Portulaca quadrifida L. on Body Weight in 
Streptozotocin induced diabetic rats. 
 
Data were expressed as mean ±SD, n=6 
Table shows the mean body weight during the study period of all groups. The mean body 
weight showed a decrease in GP2, GP3, GP2 & GP5 at 21
st
 day on comparing with 1
st
 day. 
GP2 (diabetic rats) showed a significant reduction in body weight P<0.05.when compared 
within the groups. 
 
 
 
GROUP 
 
TREATMENT 
AVERAGE BODY WEIGHT IN DAYS(gm) 
1
st
 Day 7
th
 Day 14
th
 Day 21
st
 Day 
1 Normal control 
 
147.9±2.9 
 
149.63±2.3 
 
154.5±2.4 
 
162.85±2.9 
 
2 
 
Diabetic control 
STZ (150mg/kg) 
150.65±1.0 
 
144.21±2.9 
 
138.05±2.8 
 
131.3±2.0 
 
3 
 
Glibenclamide 
(5mg/kg) 
152.06 147.9±2.3 144.18±1.2 139.05±1.07 
4 Portulaca 
quadrifida 
(200mg/kg) 
151.7±1.49 144.5±1.32 141.75±1.9 136.5±3.15 
5 
 
Portulaca 
quadrifida 
(400mg/kg) 
150.42±2.14 145.95±1.9 143.33±1.8 140.8±0.9 
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Figure 3  EFFECT ON BODY WEIGHT 
 
 
Figure 3 shows the average body weight of  STZ induced diabetic Wistar rats after 3 
weeks of treatment with ethanolic extract of Portulaca quadrifida L. 
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Table 5:  Effect of ethanolic extract of Portulaca quadrifida L on Whole blood Glucose 
(WBG)  in Streptozotocin induced diabetic rats. 
 
GROUP 
 
TREATMENT 
Whole Blood Glucose (mg/dL) 
1
st
 Day 7
th
 Day 14
th
 Day 21
st
 Day 
1 Normal control 
 
79.3±3.02 
 
75.07±0.67 
 
80.05±0.80 
 
92.32±0.44 
 
2 
 
Diabetic control 
STZ (150mg/kg) 
395.5±1.46 
 
411.05±1.52 
 
419.02±1.41 
 
423.3±1.3 
 
3 
 
Glibenclamide 
(5mg/kg) 
346.62±2.04 275.97±1.42 214.58±0.69 188.1±1.19 
4 Portulaca 
quadrifida 
(200mg/kg) 
355.22±7.53 281.81±1.01 218.48±1.44 190.93±1.06 
5 
 
Portulaca 
quadrifida 
(400mg/kg) 
411.4±4.97 383.72±1.15 252.03±1.52 185.23±9.58 
 
Data were expressed as mean ±SD, n=6 
Within group analysis: 
 The mean blood glucose showed a significant reduction in both GP3, GP4& GP5 on 
comparing 21
st
 day with 1
st
 day 
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Between group analysis: 
 When compared with GP2, the mean body glucose level was lower in GP3, GP4 & 
GP3 at day 21. On comparing GP1 with GP2, GP3, GP4 & GP5, a statistical significant 
(p<0.05) difference was observed in GP2. On comparing GP2 with GP3, GP4 & GP5, a 
statistically significant (p<0.05) difference was seen in both the groups;  
 
Figure 4 MEAN BLOOD GLUCOSE 
 
Figure 4 is the graphical representation of mean blood glucose level. 
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Table 6    LIPID PROFILE 
 
Group 
 
Treatment Cholesterol Triglycerides HDL 
 
1 
Normal control 109.2± 0.65 106.7± 0.63 16.6± 0.9 
 
2 
Diabetic control 
STZ(150mg/kg) 
155.9± 3.5 252.2± 0.9 25.12± 0.49 
 
3 
Glibenclamide 
(5mg/kg) 
130.63± 1.06 164.7± 0.6 16.6± 0.7 
 
4 
Pq (200mg/kg) 139.7± 0.6 172.9± 2.14 18.3± 0.57 
 
5 
Pq (400mg/kg) 133.4± 1.9 158.43±0.49 21.06± 1.8 
 
The value are expressed as mean± SD 
The mean cholesterol, triglycerides levels were higher in GP2, than the groups with GP3, 
GP4 & GP5. 
GP2 Vs GP3, GP4 & GP5- A significant (p< 0.05) decrease in Triglycerides Cholesterol 
level was observed 
Figure 5  LIPID PROFILE 
 
Figure 5 is the graphical representation of Lipid profile level. 
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Table 7  ASSAY OF ALP (U/ml) 
 
 
 
The values are expressed as mean ± SD, n=6 
 In GP2 the mean ALP was higher than GP1, GP3 & GP4. 
GP1 Vs GP2, GP3, GP4 &GP5- A significant (p <0.05) increase in ALP level was observed 
in GP2, GP3, GP4 & GP5. 
Figure 6 ALKALINE PHOSPHATE 
 
Figure 6 is the graphical representation of ALP levels 
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Group 
Group 
 
Treatment ALP (U/ml) 
1 
 
Normal control 0.9±0.47 
2 
 
Diabetic control 
(STZ 5mg/kg) 
7.1±0.21 
3 
 
Glibenclamide 
(5mg/kg) 
1.7±0.21 
4 
 
Pq (200mg/kg) 1.4±0.25 
5 
 
Pq (400mg/ml) 1.3±0.23 
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Table 8  ASSAY OF ACP (U/ml) 
 
Group 
 
Treatment ACP (U/ml) 
1 
 
Normal control 0.6±0.2 
2 
 
Diabetic control 
(STZ 5mg/kg) 
1.8±0.08 
3 
 
Glibenclamide 
(5mg/kg) 
0.7±0.12 
4 
 
Pq (200mg/kg) 0.6±0.15 
5 
 
Pq (400mg/ml) 0.56±0.20 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean ACP level was higher than GP1, GP3, GP4 & GP5. 
GP1 Vs GP2, GP3, GP4 & GP5 - A significant (p<0.05) decrease in ACP level was seen in 
GP3, GP4 & GP5. 
Figure 7   ACID PHOSPHATASE 
 
Figure 7 is the graphical representation of ACP level 
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Table 9     ESTIMATION OF HEXOKINASE (U/ml) ACTIVITY 
 
Group 
 
Treatment Hexokinase(U/ml) 
1 
 
Normal control 2.5±0.08 
2 
 
Diabetic control 
(STZ 5mg/kg) 
1.2±0.22 
3 
 
Glibenclamide 
(5mg/kg) 
2.3±0.09 
4 
 
Pq (200mg/kg) 2.4±0.12 
5 
 
Pq (400mg/ml) 2.56±0.17 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean hexokinase level was lower than GP1, GP3, GP4 & GP5. 
GP1 Vs GP2, GP3, GP4 & GP5- A significant (p<0.05) decrease in the HK level was 
observed in GP2 
 Figure 8  HEXOKINASE
 
Figure 8 is the graphical representation of Hexokinase activity. 
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Table 10  ESTIMATION OF G6PD (U/ml) ACTIVITY 
 
Group 
 
Treatment G6PD(U/ml) 
1 
 
Normal control 10.63±0.67 
2 
 
Diabetic control 
(STZ 5mg/kg) 
2.4±0.22 
3 
 
Glibenclamide 
(5mg/kg) 
3.56±0.2 
4 
 
Pq (200mg/kg) 3.36±0.6 
5 
 
Pq (400mg/ml) 3.43±0.25 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean G6PD level was lower than GP1, GP3, GP4 & GP5. 
GP1 Vs GP2, GP3, GP4 & GP5- A significant (p<0.05) decrease in the G6PD level was 
observed in GP2 
Figure 9  G6PD ESTIMATION 
 
Figure 9 the graphical representation of G6PD levels 
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Table 11   ESTIMATION OF LDH (U/ml) ACTIVITY 
 
Group 
 
Treatment G6PD(U/ml) 
1 
 
Normal control 13.63±0.7 
2 
 
Diabetic control 
(STZ 5mg/kg) 
25.76±1.3 
3 
 
Glibenclamide 
(5mg/kg) 
16.7±1.02 
4 
 
Pq (200mg/kg) 18.9±0.4 
5 
 
Pq (400mg/ml) 11.8±0.73 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean G6PD level was higher than GP1, GP3, GP4 & GP5. 
A significant increase was observed in LDH level when compared to other groups. 
GP1 Vs GP2, GP3, GP4 & GP5 - A significant (p<0.05) rise in the G6PD level was observed 
in GP2 
Figure 10  LDH ESTIMATION 
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Table 12  ESTIMATION OF SGOT 
 
Group 
 
Treatment SGOT(U/ml) 
1 
 
Normal control 144.05±2.0 
2 
 
Diabetic control 
(STZ 5mg/kg) 
205.1±3.15 
3 
 
Glibenclamide 
(5mg/kg) 
172.9±1.84 
4 
 
Pq (200mg/kg) 163.23±2.4 
5 
 
Pq (400mg/ml) 159.38±2.52 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean SGOT level was higher than GP1, GP3, GP4 & GP5. 
A significant increase was observed in SGOT level when compared to other groups. 
GP1 Vs GP2, GP3, GP4 & GP5 - A significant (p<0.05) rise in the SGOT level was observed 
in GP2 
Figure 11           SGOT 
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Table 13  ESTIMATION OF SGPT 
 
Group 
 
Treatment SGPT(U/ml) 
1 
 
Normal control 103.68±2.0 
2 
 
Diabetic control 
(STZ 5mg/kg) 
157.91±1.23 
3 
 
Glibenclamide 
(5mg/kg) 
116.75±0.9 
4 
 
Pq (200mg/kg) 135.97±2.7 
5 
 
Pq (400mg/ml) 122.27±0.89 
 
The values are expressed as mean ± SD, n=6 
In GP2 the mean SGPT level was higher than GP1, GP3, GP4 & GP5. 
A significant increase was observed in SGPT level when compared to other groups. 
GP1 Vs GP2, GP3, GP4 & GP5 - A significant (p<0.05) rise in the SGOT level was observed 
in GP2 
Figure 12  SGPT   
 
Figure 12 is the graphical representation of SGPT 
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Table 14  TOTAL PROTEIN 
           
Group 
 
Treatment Total protein 
 
1 
Normal control 5.96± 0.55 
 
2 
Diabetic control 
STZ(150mg/kg) 
4.31± 0.62 
 
3 
Glibenclamide (5mg/kg) 6.0±0.44 
 
4 
Pq (200mg/kg) 6.05± 0.62 
 
5 
Pq (400mg/kg) 5.98± 0.62 
 
The values are expressed as mean± SD 
 On comparing GP1 with GP2, GP3, GP4 & GP5, there was a significant (p<0.05) 
decrease in total protein. 
Figure 13 
 
Figure 13 is a graphical representation of Total protein. 
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Table 15  ESTIMATION OF UREA (mg/dl)  
 
 
 
 
 
 
 
 
The values are expressed as mean± SD 
The mean blood urea level was higher in GP2 than other groups. A significant increase was 
observed in blood urea in GP2. 
Figure 14 
 
Figure 14 is a graphical representation of blood urea 
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Group 
Urea 
Group 
 
Treatment Urea 
 
1 
Normal control 40.17± 1.74 
 
2 
Diabetic control 
STZ(150mg/kg) 
48.08± 0.82 
 
3 
Glibenclamide (5mg/kg) 36.35±1.58 
 
4 
Pq (200mg/kg) 41.8± 2.59 
 
5 
Pq (400mg/kg) 35.11±0.66 
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Table 16  ESTIMATION OF CREATININE 
 
 
 
 
 
 
The values are expressed as mean± SD 
The mean blood urea level was higher in GP2 than other groups. A significant increase was 
observed in blood urea in GP2. 
On comparing GP4 Vs GP5, there was a significant difference in creatinine (p< 0.05). 
Figure 15 
 
Figure 15 is the graphical representation of Creatinine. 
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Creatinine 
Group 
 
Treatment Creatinine 
 
1 
Normal control 0.77± 0.17 
 
2 
Diabetic control 
STZ(150mg/kg) 
1.58± 0.15 
 
3 
Glibenclamide (5mg/kg) 0.86± 0.12 
 
4 
Pq (200mg/kg) 1.1± 0.21 
 
5 
Pq (400mg/kg) 0.8± 0.16 
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HISTOPATHOLOGICAL STUDY OF LIVER 
   
      NORMAL CONTROL                                                 DIABETIC CONTROL 
 
 
                                                        GLIBENCLAMIDE 
                
   
     Portulaca quadrifida L (200mg kg)                            Portulaca quadrifida L (400mg kg) 
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HISTOPATHOLOGICAL STUDY OF PANCREAS 
                   
      NORMAL CONTROL                                  DIABETIC CONTROL 
 
               
        GLIBENCLAMIDE                                Portulaca quadrifida L (200mg kg) 
                                      
                                          
                                  Portulaca quadrifida L (400mg kg) 
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Discussion 
Diabetes mellitus is a metabolic disorder, characterized by chronic hyperglycemia 
with disturbance of carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both. Chronic hyperglycemia during diabetes leads to accelerated 
generation of reactive oxygen species (ROS) through oxidative phosphorylation during 
anaerobic glycolysis, glucose autoxidation, glucosamine pathway and a decline in the 
antioxidant defense. The ROS formed during hyperglycemia causes damage to the membrane 
lipids and proteins by lipid peroxidation and subsequent development of diabetic 
complications. Recently, there has been considerable interests in finding natural 
hypoglycemic agents from plant materials to replace synthetic ones to combat diabetic 
complications are going on relentlessly.(49)  
The goals of treatment for diabetes are to reduce and control blood glucose levels, 
relieve the symptoms of disease, and prevent complications. The use of herbal medicine by 
the suffers of chronic diseases is encouraged by the concern about the adverse effects of 
chemical drugs and treatment using medicines of natural origin appears to offer gentler 
means of managing such diseases(50).  
Over 150 plant extracts and some of the active principle including flavonoids are 
known to be used for the treatment of diabetes. In our study the whole plant extract of 
chemical constituents such as Carbohydrates, Flavonoids, Terpenes, Glycosides, Tannins, 
Saponins, Mucilage, Proteins and Sterols were used. 
Acute toxicity study revealed that the ethanolic extract of Potulaca quadrifida L. was 
relatively nontoxic upto 2000mg/kg/bw p.o indirectly pronouncing safety profile of the 
extract. 
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Portulaca quadrifida L. is a tropical herb/forb which has been traditionally used in the 
management of DM. this present study has been undertaken to evaluate its antidiabetic 
property by preliminary phytochemical analysis, in vitro, Toxicological and in vivo studies in 
Wistar albino rats. 
The phytochemical analysis of ethanolic extract of Portulaca quadrifida L. showed 
the presence of Alkaloids, Flavonoids, Tannins, Protein, Carbohydrates, Mucilage, 
Phytosterols, Saponins, Glycosides and Terpenoids. 
Glucose adsorption capacity of Portulaca quadrifida L. extract showed maximum 
glucose bound at 50mM of glucose solution (53nm). Published research suggests that there is 
a direct relationship between a plant’s ability to inhibit glucose absorption and viscosity of 
the  plant’s constituents such as soluble polysaccharides, supported by Gallagher et al.,(2003) 
and Wood et al., (1994)(51) 
The invitro antidiabetic evaluation was assessed by glucose diffusion assay.  
Portulaca quadrifida L. ethanolic extract showed maximum decrease in glucose diffusion 
when compared to control values. Glucose diffusion is useful invitro index to predict the 
effect of plant fibers on the delay in glucose absorption in GI tract. In addition to glucose 
adsorption, the retardation in glucose diffusion might be attributed to the physical obstacle 
presented by fiber particles towards glucose molecules and entrapment of glucose within the 
network formed by fibers. Based on this invitro study result, ethanolic extract of Portulaca 
quadrifida L. was selected for invivo study. 
Vehicle control animals were found to be almost stable in their body weight but 
diabetic induced rats showed significant reduction in body weight. The administration of 
Portulaca quadrifida L. whole plant extracts (200,400 mg/kg) and Glibenclamide (5mg/kg) 
to the diabetic rats restored the changes in the body weight. On comparing 200mg Vs 400mg, 
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there was a significant difference in body weight (P<0.05). The dose dependent antidiabetic 
property of the ethanolic extract of Portulaca quadrifida L. exhibited improvement in body 
weight. 
Plants may act on blood glucose through different mechanisms, some of them may 
have insulin-like substances.(52) Some may stimulate β-cells to produce more insulin and 
others may increase β-cells in the pancreas by activating regeneration of pancreatic cells. The 
fiber of the plants may also interfere with carbohydrate absorption; thereby affecting blood 
glucose. 
In our study, after the administration of extract (200,400mg/kg), the fall in fasting 
blood glucose was evident at the end. This fall in fasting blood glucose level progressively 
increases till the end of 3rd week. 
When the reduction glucose level with 200mg/kg & 400mg/kg were compared, there 
was a statically significant reduction in blood glucose levels (P<0.05) with 400mg of the 
extract. 
The integrity of the lysosomal membrane is crucial to the maintenance of normal 
levels of lysosomal glycohydrolases in tissue and body fluids. A compromise of lysosomal 
membrane integrity may lead to an undesirable elevation of lysosomal enzymes in both intra- 
and extra-cellular space, which could pave the way for cellular and tissue disorders. Eg. 
Diabetes, arthritis, allergic response etc.(53). In the present study the diabetic control group, 
there was an increase in alkaline phosphate and acid phosphate. This may due to the damage 
of the lysosomal membrane in the diabetic animals. But in the Portulaca quadrifida L. extract 
treated group, there was a significant reduction of these enzyme level which reveal the 
protective nature of the plant source. 
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The hexokinase involved in the phosphorylation step of glucose in glycolysis. Hepatic 
hexokinase is the most sensitive indicator of the glycolytic pathway in diabetes and its 
increased level can increase the utilization of blood glucose for glycogen storage in liver. 
Glucose-6-phosphate dehydrogenase activity was decreased in DM, resulting in diminished 
functioning of HMP pathway and there by the production of reducing equivalent such as 
NADH and NADPH.(54) In the present study, the hexokinase and Glucose-6-phosphate 
dehydrogenase activity were reduced in diabetic control group. The Portulaca quadrifida L. 
extract treated group, there was an increase in the activity of both hexokinase and Glucose-6-
phosphate dehydrogenase. This shows that the Portulaca quadrifida L. improves the activity 
of carbohydrate metabolizing enzymes (HK & G6PD). 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that catalyzes the conversion of 
pyruvate to lactate in anaerobic glycolysis, which is subsequently converted to glucose in 
glucogenic flux. Increased activity of lactate dehydrogenase interferes with normal glucose 
metabolism and insulin secretion secretary defects in diabetes.(55) In the present study, the 
LDH activity was significantly elevated in diabetic control group. An increase in LDH 
activity is observed in diabetes due to impairment in glucose stimulated insulin secretion. In 
the Portulaca quadrifida L. extract treated group, the LDH activity was suppressed 
significantly. The suppression of LDH activity shows the beneficial effects of plant source. 
The levels of total serum cholesterol, triglycerides and HDL were raised in diabetic 
rats which were lowered significantly with the treatment of Portulaca quadrifida L. On 
comparing groups 3,4,5 with group 2 there was a significant reduction in total cholesterol, 
triglycerides and HDL level (P<0.05). This shows that ethanolic extract of Portulaca 
quadrifida L. is effective in reducing the total cholesterol, triglycerides, HDL levels (P<0.05) 
in streptozotocin induced diabetic rats and its hypolipidemic effect could represent a 
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protective mechanism against the development of atherosclerosis which is usually associated 
with diabetes. 
Ghosh and Suryawanshi, 2001 observed elevation in transaminase activity (SGOT 
and SGPT) in liver and kidney in diabetic rats.(56) Increased gluconeogenesis and ketogenesis 
observed in diabetic may be due to the high level in the activities of these transaminases. 
Similarly in our study also there was an increase in SGOT and SGPT in group 2 animals 
(Diabetic control). The restoration of SGOT and SGPT to their respective normal levels was 
seen after the treatment with both Glibenclamide and ethanolic extract of Portulaca 
quadrifida L. This supports the antidiabetogenic effect of Portulaca quadrifida L. Moreover, 
SGOT and SGPT levels also act as indicators of liver function and restoration of these 
parameters to normal levels indicate normal functioning of liver. 
On comparing groups 3, 4 and 5 with group 2, there was a significant difference 
(P<0.05) in total protein. In diabetic control rats, there was a decrease in serum protein. 
Portulaca quadrifida L. extract prevented the reduction of serum protein in groups 4& 5. 
Group 5 showed a statistically significant difference when compared to group 4 (P<0.05). 
Blood urea and creatinine was elevated in group 2 (Diabetic control). When 
comparing the groups 3, 4 & 5 with group 2, there was a significant difference (P<0.05) in 
blood urea and creatinine. This shows that in the groups which received Portulaca quadrifida 
L. extract, there was no significant increase in urea and creatinine. 
The renewal of β cells in diabetes has been studied in different animal models. The 
total β-cells mass reflects the balance between the renewal and loss of these cells. It has been 
suggested that regeneration of islet β-cells following destruction by streptozotocin, may be 
the primary cause of the recovery of streptozotocin injected guinea pigs from the effect of the 
drug(57). 
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In our studies, the damage of pancreas in STZ treated diabetic control (Figure17) and 
regeneration of β-cells by Glibenclamide (Figure16) was observed. The regeneration in 
ethanolic extract of Portulaca quadrifida L. was comparable with Glibenclamide; Portulaca 
quadrifida L. extract (400mg/kg) was showed better regeneration than (200mg/kg) of 
Portulaca quadrifida L. extract.  
Photomicrographical data in our studies reinforce healing of pancreas by ethanolic 
extract of 200mg/kg and 400mg/kg as a plausible mechanism of their antidiabetic activity. 
The data of our studies suggests that Portulaca quadrifida L. has beneficial effects in 
diabetes mellitus holding the hope of a new generation for anti-diabetic drugs. 
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CONCLUSION 
 From the present study we conclude that the preliminary phytochemical analysis of 
Portulaca quadrifida L. indicated the presence of alkaloids, flavonoids, proteins, 
saponins, carbohydrates, terpenoids, mucilage, glycosides, tannins and phytosterols. 
 Invitro Glucose adsorption assay of Portulaca quadrifida L. extract was evaluated 
using GOD-POD kit. 
 Invitro Glucose diffusion properties of Portulaca quadrifida L. extract was evaluated 
using dialysis membrane and GOD-POD kit. 
 Ethanolic extract of Portulaca quadrifida L. was safe in dose upto 2000mg/kg by 
acute toxicity study and there was no toxic effects produced. 
 The ethanolic extract of Portulaca quadrifida L. exhibited significant antidiabetic 
activity in Streptozotocin induced diabetic rats. 
 In vivo studies of Portulaca quadrifida L. ethanolic extract revealed the glucose 
lowering effect& improved activity of carbohydrate metabolizing enzymes.  Thus it 
was concluded that the ethanolic extract of Portulaca quadrifida L. has anti-diabetic 
activity. 
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